946832-34-4
946832-34-4 structure
- Name: Racotumomab
- Chemical Name: Racotumomab
- CAS Number: 946832-34-4
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2023-01-18 13:56:51
- Modify Date: 2025-08-21 07:02:31
-
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3].
| Name | Racotumomab |
|---|
| Description | Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death[4]. |
| In Vivo | Racotumomab (50 μg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model[2]. Racotumomab (50 μg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft[3]. Racotumomab (50-200 μg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft[3]. Animal Model: 3LL cell (s.c.) mice xenograft[3] Dosage: 50 μg/dose, together with Pemetrexed (100 mg/kg) Administration: Subcutaneous injection (s.c.) Result: Reduced lung nodules. |
| References |
| No Any Chemical & Physical Properties |